These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24987057)

  • 21. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.
    Kitano S; Kageyama S; Nagata Y; Miyahara Y; Hiasa A; Naota H; Okumura S; Imai H; Shiraishi T; Masuya M; Nishikawa M; Sunamoto J; Akiyoshi K; Kanematsu T; Scott AM; Murphy R; Hoffman EW; Old LJ; Shiku H
    Clin Cancer Res; 2006 Dec; 12(24):7397-405. PubMed ID: 17189412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.
    Ishizaki H; Song GY; Srivastava T; Carroll KD; Shahabi V; Manuel ER; Diamond DJ; Ellenhorn JD
    J Immunother; 2010; 33(6):609-17. PubMed ID: 20551836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction: p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses.
    Clin Cancer Res; 2017 Jan; 23(1):322. PubMed ID: 28049162
    [No Abstract]   [Full Text] [Related]  

  • 30. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.
    Bathke B; Pätzold J; Kassub R; Giessel R; Lämmermann K; Hinterberger M; Brinkmann K; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Immunology; 2018 Jun; 154(2):285-297. PubMed ID: 29281850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between
    Booth JS; Goldberg E; Patil SA; Greenwald BD; Sztein MB
    Hum Vaccin Immunother; 2019; 15(6):1409-1420. PubMed ID: 30836838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
    Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
    Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
    Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
    Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
    Diniz MO; Lasaro MO; Ertl HC; Ferreira LC
    Clin Vaccine Immunol; 2010 Oct; 17(10):1576-83. PubMed ID: 20739505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.